Daniel A Shoskes1, Jessica Altemus2, Alan S Polackwich3, Barbara Tucky3, Hannah Wang4, Charis Eng5. 1. Department of Urology, Glickman Urological Institute, Cleveland Clinic, Cleveland, OH 44195. Electronic address: dshoskes@mac.com. 2. Genomic Medicine Institute, Cleveland Clinic, Cleveland, OH 44195. 3. Department of Urology, Glickman Urological Institute, Cleveland Clinic, Cleveland, OH 44195. 4. Genomic Medicine Institute, Cleveland Clinic, Cleveland, OH 44195; Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, OH 44195. 5. Genomic Medicine Institute, Cleveland Clinic, Cleveland, OH 44195; Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, OH 44195; Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH 44106.
Abstract
OBJECTIVE: To study the urinary microbiome of patients with Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) compared with controls. METHODS: We identified 25 patients with CP/CPPS and 25 men who were either asymptomatic or only had urinary symptoms. Midstream urine was collected. Symptom severity was measured with the National Institutes of Health Chronic Prostatitis Symptom Index and clinical phenotype with UPOINT. Total DNA was extracted from the urine pellet and bacterial-specific 16Sr-DNA-capture identified by MiSeq sequencing. Taxonomic and functional bioinformatic analyses used principal coordinate analysis (PCoA)/MacQIIME, LEfSe, and PiCRUSt algorithms. RESULTS: Patients and controls were similar ages (52.3 vs 57.0 years, P = .27). For patients, median duration was 48 months, mean Chronic Prostatitis Symptom Index was 26.0, and mean UPOINT domains was 3.6. Weighted 3D UniFrac PCoA revealed tighter clustering of controls distinct from the wider clustering of cases (P = .001; α-diversity P = .005). Seventeen clades were overrepresented in patients, for example, Clostridia, and 5 were underrepresented, eg, Bacilli, resulting in predicted perturbations in functional pathways. PiCRUSt inferred differentially regulated pathways between cases and controls that may be of relevance including sporulation, chemotaxis, and pyruvate metabolism. PCoA-derived microbiomic differences were noted for neurologic/systemic domains (P = .06), whereas LEfSe identified differences associated with each of the 6 clinical features. CONCLUSION: Urinary microbiomes from patients with CP/CPPS have significantly higher alpha(phylogenetic) diversity which cluster differently from controls, and higher counts of Clostridia compared with controls, resulting in predicted perturbations of functional pathways which could suggest metabolite-specific targeted treatment. Several measures of severity and clinical phenotype have significant microbiome differences.
OBJECTIVE: To study the urinary microbiome of patients with Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) compared with controls. METHODS: We identified 25 patients with CP/CPPS and 25 men who were either asymptomatic or only had urinary symptoms. Midstream urine was collected. Symptom severity was measured with the National Institutes of Health Chronic Prostatitis Symptom Index and clinical phenotype with UPOINT. Total DNA was extracted from the urine pellet and bacterial-specific 16Sr-DNA-capture identified by MiSeq sequencing. Taxonomic and functional bioinformatic analyses used principal coordinate analysis (PCoA)/MacQIIME, LEfSe, and PiCRUSt algorithms. RESULTS:Patients and controls were similar ages (52.3 vs 57.0 years, P = .27). For patients, median duration was 48 months, mean Chronic Prostatitis Symptom Index was 26.0, and mean UPOINT domains was 3.6. Weighted 3D UniFrac PCoA revealed tighter clustering of controls distinct from the wider clustering of cases (P = .001; α-diversity P = .005). Seventeen clades were overrepresented in patients, for example, Clostridia, and 5 were underrepresented, eg, Bacilli, resulting in predicted perturbations in functional pathways. PiCRUSt inferred differentially regulated pathways between cases and controls that may be of relevance including sporulation, chemotaxis, and pyruvate metabolism. PCoA-derived microbiomic differences were noted for neurologic/systemic domains (P = .06), whereas LEfSe identified differences associated with each of the 6 clinical features. CONCLUSION: Urinary microbiomes from patients with CP/CPPS have significantly higher alpha(phylogenetic) diversity which cluster differently from controls, and higher counts of Clostridia compared with controls, resulting in predicted perturbations of functional pathways which could suggest metabolite-specific targeted treatment. Several measures of severity and clinical phenotype have significant microbiome differences.
Authors: J Curtis Nickel; Michael A Gorin; Partin Alan W; Stacy Loeb; Shapiro Ellen; Michael B Chancellor; Dean G Assimos; Michael K Brawer; Benjamin M Brucker Journal: Rev Urol Date: 2016
Authors: Lisa Karstens; Mark Asquith; Vincent Caruso; James T Rosenbaum; Damien A Fair; Jonathan Braun; W Thomas Gregory; Rahel Nardos; Shannon K McWeeney Journal: Nat Rev Urol Date: 2018-12 Impact factor: 14.432
Authors: Nicolaas H Fourie; Dan Wang; Sarah K Abey; Amy L Creekmore; Shuangsong Hong; Christiana G Martin; John W Wiley; Wendy A Henderson Journal: Gut Microbes Date: 2017-01-06